Sign In
Buy BCTX
$3.01
+0.110 (+3.79%)
At Close: Jun 22, 2026
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
04:05pm, Tuesday, 31'st Mar 2026
PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell”), a clinical-stage biotechno
PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage b
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
07:30am, Tuesday, 10'th Mar 2026
PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
04:04pm, Thursday, 05'th Mar 2026
PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX , BCTXL ) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage b
Briacell Therap (NASDAQ:BCTX) Sees Significant Decline in Short Interest
04:10am, Sunday, 01'st Mar 2026
Briacell Therap (NASDAQ: BCTX - Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 102,666 sh
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
05:30pm, Wednesday, 18'th Feb 2026
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnol
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
07:30am, Tuesday, 17'th Feb 2026
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), clinic
BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
07:30am, Wednesday, 28'th Jan 2026
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clin
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
07:30am, Tuesday, 27'th Jan 2026
9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations No Bria
Briacell Therap (NASDAQ:BCTX) versus Exact Sciences (NASDAQ:EXAS) Head-To-Head Survey
02:48am, Friday, 23'rd Jan 2026
Exact Sciences (NASDAQ: EXAS - Get Free Report) and Briacell Therap (NASDAQ: BCTX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies b
BriaCell Therapeutics Announces Closing of US$30 million Public Offering
04:05pm, Thursday, 15'th Jan 2026
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
Short Interest in Briacell Therap (NASDAQ:BCTX) Expands By 174.9%
03:52am, Wednesday, 14'th Jan 2026
Briacell Therap (NASDAQ: BCTX - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totaling 281,381 shares, an increase
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
09:00pm, Tuesday, 13'th Jan 2026
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient
07:30am, Tuesday, 13'th Jan 2026
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-st
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
07:30am, Thursday, 18'th Dec 2025
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
